Amniotic Membrane Market Size

Global Amniotic Membrane Market Overview

The amniotic membrane market size was valued at USD 1.2 Billion in 2022. The amniotic membrane industry is projected to grow from USD 1.25 Billion in 2023 to USD 1.78 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 16.26% during the forecast period (2023 - 2032).

Increasing analysis on stem cell biology and regenerative medicine and an expansion in the number of accident and trauma cases are the key market drivers enhancing the market growth.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

In March 2023, NuVision, a health tech company in Nottingham, received £1.1m for its wound-healing dressing and contact lenses for healing eye injuries that are made from the inner side of the placenta. In January 2023, Celularity, a US-based biomaterial products and placenta-derived allogenic cell therapies company and CH Trading Group, an international trading company, entered into a distribution agreement with Tamer Group, which is a key healthcare distributor in the Middle East.In November 2022, Verséa Ophthalmics introduced several products like Biovance – a hybrid next-generation amniotic membrane comprised of three layers of amnion called a triple layer.MiMEdx Group, Inc., the first to introduce placental biologics, began selling Amnioeffect. 

The effect is made up of chorion/amnion/intermediate membrane layers of the placenta by Purion process involving triple layer graft. The products can enhance surgical wound recovery.The SAS announced an agreement with Akorn Operating Company LLC, labeling them as branded ophthalmic products, including AcellFX, among others, giving them a presence in the US market. AcellFX means an acellular amniotic membrane covering or ocular surface repair.Amnio Technology also launched two brand new PalinGen membrane products- Dual Layer PalinGen X-Membrane & PalinGen Dual-Layer Membrane in February this year; both are homologous use only chorion-free & minimally manipulated.TissueTech acquired Amniox Medical, known as a pioneer developer of human birth tissue-based products, early this year in January 2022. 

This way, TissueTech would strengthen its presence within the market’s amniotic membrane sector and increase its product offerings.In June 2021, Amniox Medical launched an awareness campaign aimed at reducing the cost of care associated with wound healing caused by the burning of tissues. Moreover, burns are significantly reduced as they minimize inflammation and reduce pain. Hence, creating awareness about these advantages will lead to increased market growth.

Amniotic Membrane Market Trends

• The rising incidence of burn injuries is driving the market growth

Market CAGR for amniotic membranes is driven by increased demand for wound care biologics, including amniotic membranes. According to the WHO, most burn cases occur in low- and middle-income economies, and almost two-thirds appear in the WHO African and Southeast Asian regions. For instance, 1 million people in India suffer from moderate and severe burns yearly. The high incidence of burns is also high in other Southeast Asian regions, including Bangladesh and Nepal. An estimated 173,000 children suffer from mild or extreme burns in Bangladesh annually. In Nepal, burns are the second-most expected wound, accounting for 5% of all disabilities.

Additionally, increasing awareness in recent years has led to an increasing number of transplants, resulting in rising demand for these tissue-based solutions. This awareness has also increased in several donations, driving market revenue growth. For instance, In June 2021, Amniox Medical, Inc., a Tissue Tech, Inc. company and a pioneer in the clinical use of human birth tissue products, launched a new awareness campaign highlighting Amniox's comprehensive family of human birth tissue-based products to facilitate wound healing and minimize the related cost of care. The campaign highlights evidence-based quality management while examining the financial strain that treating complex wounds takes on the healthcare systems.

An expansion in the number of R&D activities for expanding the efficacy of amniotic membranes and developing new products is expected to assist in the market growth. For instance, in November 2020, an American regenerative medicine firm, Amnio Technology, started Phase II clinical tests to try the efficacy of their product PalinGen, an amniotic membrane allograft utilized for treating diabetic ulcers.

Moreover, physical beauty has become one of the most important components of one's personality, and maintaining a faultless appearance is one of today's most popular trends. Amniotic tissues aid in the healing of wounds and burns. In recent years, Indians have embraced many ophthalmology and cosmetic surgical treatments, likely to expand the country's amniotic membrane product suppliers. Due to increased amniotic dry eye therapy, India's market is predicted to grow by double digits. Amniotic membranes are often used as a biological bandage to heal or replace injured eye tissues during eye procedures. The expanding popularity of dry eye amniotic membrane therapy, increased awareness among the general public, increasing amniotic membrane application, and growing skin care treatments will all likely boost the amniotic membrane market revenue.

Amniotic Membrane Market Segment Insights

Amniotic Membrane Type Insights

The amniotic membrane market segmentation, based on type, includes cryopreservation amniotic membrane and lyophilized amniotic membrane. The cryopreservation amniotic membrane segment dominated the market, accounting for 35% of market revenue (0.44 Billion). In developing economies, category growth is driven due to its elevated effectiveness and high adoption rates globally. This type of cryopreserved membrane is usually held in a cell culture medium that comprises 50% glycerol at a temperature of -80 °C. However, lyophilized amniotic membrane is the fastest-growing category owing to the arrangement of this membrane has not been associated with any substantial adverse reactions or unpredictable long-term consequences.

Amniotic Membrane Application Insights

The amniotic membrane market segmentation, based on application, includes surgical wounds, ophthalmology, stem cell biology, regenerative medicine, prenatal diagnosis, and others. The surgical wounds category generated the most income (70.4%). This is majorly the rising number of chronic and infectious diseases and a rise in surgeries. Amniotic membranes are used in reconstructive surgeries to promote healing and reduce scarring. However, ophthalmology is the fastest-growing category due to the increasing use of tissue-based products in ocular treatments.

Amniotic Membrane End User Insights

The amniotic membrane market segmentation, based on end users, includes hospitals & clinics, ambulatory surgical centers, research centers & laboratories, and others. The hospital & clinics category generated the most income over the forecast period. This is majorly due to frequent patient visits as hospitals are the immediate care settings enabling effortless treatment for various diseases. However, research centers & laboratory is the fastest-growing category due to the growing government initiatives to improve the healthcare infrastructure of the middle-class population in developing economies.

Figure 1: Amniotic Membrane Market by End-User, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Amniotic Membrane Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American amniotic membrane market will dominate, owing to an increased focus on alternative technologies and the adoption of advanced technologies in this region. Further, the US amniotic membrane market held the largest market share, and the Canada amniotic membrane market was the fastest-growing market in the North America region.

Further, the key countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: AMNIOTIC MEMBRANE MARKET SHARE BY REGION 2022 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe amniotic membrane market accounts for the second-largest market share owing to high healthcare expenditure by local governments and highly developed healthcare infrastructure in this region. Further, the German amniotic membrane market held the largest market share, and the UK amniotic membrane market was the fastest-growing market in the European region.

The Asia-Pacific amniotic membrane Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to a rise in accidents and a growing need for aesthetic surgery, and the increasing use of amniotic membranes during eye surgery to avoid the need for glasses in this region. Moreover, China amniotic membrane market held the largest market share, and the India amniotic membrane market was the fastest-growing market in the Asia-Pacific region.

Amniotic Membrane Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development to expand their product lines, which will help the amniotic membrane market grow even more. Market participants are also undertaking several strategic activities to enhance their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the amniotic membrane industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the amniotic membrane industry to benefit clients and increase the market sector. Major players in the amniotic membrane market, including Alliqua BioMedical Inc., Applied Biologics LLC, Amnio Technology, LLC, Human Regenerative Technologies, LLC, Katena Products, Inc, DermaSciences, and others, are attempting to increase market demand by investing in research and development operations.

Organogenesis Holdings Inc. operates as a holding firm. The organization, through its subsidiaries, focuses on developing, manufacturing, and commercializing drugs and medicines for surgical, wound care, and sports medicine markets. Organogenesis Holdings helps consumers in the United States and Switzerland. In May 2021, Organogensis, Inc announced the launch of ReNu, an amniotic suspension. Furthermore, the US Food and Drug Administration granted the firm the Regenerative Medicine Advanced Therapy designation for use in knee osteoarthritis.

Laboratoires Thea SA is a pharmaceutical company that researches, develops, manufactures, and commercializes various eye care products. The company's products find application in diagnosing and treating ophthalmic diseases such as dry eye, allergies, glaucoma, ocular and eyelid hygiene, eye surgery, and violations of the posterior segment. Its product portfolio includes eye drops, ophthalmic gels, sterile compresses and micellar solutions. Thea markets these products under the brand names Blephagel, Blephasteam, Nutrof, ABAK, Blephasol, and Blephaclean. The company markets products through sales organizations and distributors. In January 2022, Laboratoires Thea SAS signed an agreement to purchase seven branded ophthalmic products from Akorn Operating Company LLC, including AcellFX (acellular amniotic membrane), which provides a protective environment or covering for repair to the ocular surface.

Key Companies in the Amniotic Membrane market include

• Tissue-Tech Inc. (US)


• Applied Biologics (US)


• LifeLike BioTissue (US)


• Celularity Inc, (U.S)


• Labtician Ophthalmics Inc. (Canada)


• Smith+Nephew (UK)


• Stryker (US)


• WWW.SURGILOGIX.COM. (US)


• Integra LifeSciences (U.S)


• MiMedx (US)


• Skye Biologics Holdings LLC (US)


• Amniox Medical Inc (U.S)


• Human Regenerative Technologies LLC (US)


• Katena Products Inc (US)


• Amnio Technology, LLC (US)

Amniotic Membrane Industry Developments

February 2022:Amnio Technology, a leader in the development of and distribution of amniotic tissue allografts, launched two new PalinGen membrane products, PalinGen Dual-Layer Membrane and Dual Layer PalinGen X-Membrane. The new allografts, like the entire family of PalinGen membrane products, are minimally manipulated, homologous use, and chorion-free. The PalinGen Dual-Layer Membrane and Dual-Layer PalinGen X-Membrane are indicated for patients suffering from non-healing acute and chronic wounds and complex and open surgical wounds and burns.

May 2021:VIVEX Biologics, Inc., a leading regenerative medicine firm specializing in the development of naturally sourced treatments, launched VIAGENEX, which is a family of amniotic allografts processed to retain the inherent mechanical properties of amniotic tissue and a rich supply of extracellular matrix, growth factors, and cytokines.

Amniotic Membrane Market Segmentation

Amniotic Membrane Type Outlook

• Cryopreservation Amniotic Membrane


• Lyophilized Amniotic Membrane

Amniotic Membrane Application Outlook

• Surgical Wounds


• Ophthalmology


• Stem Cell Biology


• Regenerative Medicine


• Prenatal Diagnosis


• Others

Amniotic Membrane End User Outlook

• Hospital & Clinics


• Ambulatory Surgical Centers


• Research Centers & Laboratory


• Others

Amniotic Membrane Regional Outlook

• North America


• US


• Canada


• Europe


• Germany


• France


• UK


• Italy


• Spain


• Rest of Europe


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East0
  
  
  • Africa
  
  
  • Latin America